Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06806930 · ClinicalTrials.gov registry record · Phase 2

Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)

A Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III, sponsored by George Washington University.

Recruiting
Registry status
Phase 2
Development phase
90
Enrollment target
1
Study location

NCT06806930 is a Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III that is actively recruiting participants, run by George Washington University. The registered enrollment target is 90 participants, below the 178-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (49% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06806930, a Phase 2 study of Breast Cancer Stage II and Breast Cancer Stage III, is actively recruiting participants, sponsored by George Washington University.

RECRUITING
Registry status
Phase 2
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: 1. How breast cancer responds to endocrine therapy given prior to surgery? 2. To predict tumor pre-operative endocrine prognostic index (PEPI) score for subjects enrolled in cohort B or C Participants with early-stage breast cancer (Stage I-III) who are eligible for Neoadjuvant Endocrine Therapy (NET) will be enrolled in the study. Participants will: * receive endocrine therapy as part of regular care for breast cancer * consent to samples of blood and tissue evaluation to determine how endocrine therapy effects the tumor * participate in this research anywhere from 2 weeks to 1 year, depending on duration of endocrine therapy and when surgery will be performed

Conditions Studied

Breast Cancer Stage II Breast Cancer Stage III Breast Cancer Stage I Carcinoma, Breast

Interventions

  • DRUG Neoadjuvant endocrine therapy

Study Locations (1)

District of Columbia

  • George Washington-Medical Faculty Associates - Washington D.C.

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2024-10-01
Est. Completion 2028-10
Phase Phase 2

Sponsor

George Washington University

133 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06806930

The ClinicalTrials.gov registry entry for NCT06806930 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 178-participant average among 22 other Breast Cancer Stage II trials with a reported enrollment target (49% lower). The listed sponsor is George Washington University, which has 133 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Breast Cancer Stage II appearing as the primary indexed condition, and to 1 intervention - of which Neoadjuvant endocrine therapy is the first listed.

NCT06806930 reports 1 study location spanning 1 distinct geographic area - top geographies include District of Columbia.

Frequently Asked Questions

What is clinical trial NCT06806930 about?

NCT06806930 is a clinical study titled "Predicting Response to Neoadjuvant Endocrine Therapy (Neo-PREDICT)". The goal of this clinical trial is to determine how the duration of hormone blocking (endocrine) therapy given prior to surgery (called "neoadjuvant" treatment) affects breast cancer. The main questions the trial aims is answer are: 1. How breast cancer responds to endocrine therapy given prior to ...

What is the current status of trial NCT06806930?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2024-10-01. Estimated completion is 2028-10.

What conditions does trial NCT06806930 study?

This clinical trial studies the following conditions: Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage I, Carcinoma, Breast.

What interventions are being tested in trial NCT06806930?

The interventions under investigation include: Neoadjuvant endocrine therapy (DRUG).

Who is sponsoring clinical trial NCT06806930?

This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06806930 being conducted?

This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer Stage II

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer Stage II

All registered trials for this condition

Breast Cancer Stage III

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.